Legal & General Group Plc purchased a new position in Zenas BioPharma, Inc. (NASDAQ:ZBIO – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 20,023 shares of the company’s stock, valued at approximately $508,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Quarry LP boosted its position in Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after buying an additional 291 shares during the period. Russell Investments Group Ltd. bought a new position in Zenas BioPharma in the 3rd quarter worth about $30,000. Quantbot Technologies LP purchased a new position in shares of Zenas BioPharma during the second quarter worth approximately $49,000. BNP Paribas Financial Markets increased its position in shares of Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after acquiring an additional 1,716 shares during the period. Finally, Sei Investments Co. bought a new stake in shares of Zenas BioPharma during the second quarter valued at approximately $118,000.
Analyst Ratings Changes
A number of analysts recently issued reports on the company. Citigroup reiterated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Guggenheim restated a “buy” rating and set a $55.00 price objective on shares of Zenas BioPharma in a report on Friday, August 14th. Wall Street Zen raised Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Wedbush reiterated an “outperform” rating and issued a $45.00 target price on shares of Zenas BioPharma in a report on Friday, August 14th. Finally, Weiss Ratings downgraded Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Zenas BioPharma has a consensus rating of “Moderate Buy” and an average price target of $45.71.
Zenas BioPharma Price Performance
Shares of ZBIO opened at $33.05 on Wednesday. The company has a 50 day moving average price of $30.91 and a 200-day moving average price of $24.59. Zenas BioPharma, Inc. has a fifty-two week low of $13.50 and a fifty-two week high of $44.60. The stock has a market capitalization of $2.15 billion, a PE ratio of -3.68 and a beta of -1.04. The company has a debt-to-equity ratio of 1.57, a quick ratio of 9.93 and a current ratio of 9.93.
Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $15.00 million. Equities analysts predict that Zenas BioPharma, Inc. will post -5.81 earnings per share for the current fiscal year.
Zenas BioPharma Profile
Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.
Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.
Further Reading
- Five stocks we like better than Zenas BioPharma
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
